Conference Presentations

| 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |

2017

The American Society of Gene and Cell Therapy Annual Conference, Washington, DC. 05-10 to 05-13.

  1. Delivery of Therapeutic Monoclonal Antibody Genes for Prophylaxis of Respiratory Syncytial Virus Infection. Antepowicz A et al.
     
  2. A Poly-Functional Gene Delivery System for Cystic Fibrosis. Montier T et al.
     
  3. Development of Recombinant Adeno-Associated Viral Vector (rAAV) for Passive Immunisation Against Ebola. Tan TK et al.
     

2016

The European Society of Gene and Cell Therapy Conference, Florence. 10-18 to 10-21.

  1. Dissecting enhancer/promoter function for high-level, persistent transgene expression Gill DR et al.
     

European Cystic Fibrosis Conference, Basel. 06-08 to 06-11.

  1. How to take gene therapy further? Davies et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Washington, DC. 05-04 to 05-07.

  1. Minicircles Are Similar To Plasmids In Providing High Level, Long-Term Expression In The Lung . Gill DR et al.
     
  2. Preparation for a First-in-Man Lentivirus Trial in Cystic Fibrosis Patients. Griesenbach U et al.
     
  3. Lung antibody factory to provide long-term passive immunity to influenza. Tan TK et al.
     

The British Society of Gene Therapy Annual Conference, London. 04-15 .

  1. Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies Antepowicz A et al.
     
  2. Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency. Pytel KM et al.
     

Radcliffe Department of Medicine, Annual Symposium, Oxford. 02-23 .

  1. Cystic Fibrosis Gene Therapy Clinical Trial Demonstrates Beneficial Effect on Lung Function. Pringle IA et al.
     

2015

NDCLS Science Day, Oxford. 11-25 to 11-25.

  1. Cystic Fibrosis Gene Therapy Clinical Trial Demonstrates Beneficial Effect on Lung Function. Pringle IA et al.
     

The North American Cystic Fibrosis Conference, Phoenix. 10-08 to 10-10.

  1. A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis. Alton EW et al.
     
  2. Repeated Administration of the Non-Viral Gene Transfer Agent pGM169/GL67A Does Not Induce Anti-CFTR or Anti-Plasmid Immunoresponses. Griesenbach U et al.
     
  3. Moving lentiviral-based gene therapy into a first-in-man CF trial. Griesenbach U et al.
     
  4. Production of rSIV-F/HN: a new Lentivirus vector for CF gene therapy. Hyde SC et al.
     

UK Cystic Fibrosis Conference, Manchester. 09-22 to 09-23.

  1. Moving gene therapy into CF patients. Alton EW et al.
     
  2. Current issues around LCI (Lung Clearance Index). Davies JC et al.
     

The European Society of Gene and Cell Therapy Conference, Helsinki. 09-17 to 09-20.

  1. A Phase 2b clinical trial of non-viral gene therapy in Cystic Fibrosis patients: randomized, double-blind, placebo-controlled repeated aerosol delivery to the lungs. Gill DR et al.
     

European Cystic Fibrosis Conference, Brussels. 06-10 to 06-13.

  1. Gene Therapy: Moving to the Clinic. Alton EW et al.
     

The British Society of Gene Therapy Annual Conference, Glasgow. 06-09 to 06-11.

  1. A Phase IIb double-blind, placebo-controlled trial of non-viral mediated gene therapy for cystic fibrosis. Griesenbach U et al.
     
  2. Delivery of host targeted miRNA therapeutics for the treatment of respiratory viral infections. McLachlan G et al.
     
  3. Therapeutic levels of alpha-1-antitrypsin following gene therapy with F/HN pseudotyped simian immunodeficiency virus. Paul-Smith M et al.
     
  4. Production of FVIII in the lungs. Pytel KM et al.
     

The American Society of Gene and Cell Therapy Annual Conference, New Orleans. 05-13 to 05-16.

  1. The Significance of Academia-Industry Collaboration in Translational Research: A Survey of Over 300 PIs Who Have Received Industry Funding. Davie NL et al.
     
  2. Scalable, Animal-Free, Suspension-Based Production of SIV Lentiviral Vectors. Hyde SC et al.
     
  3. F/HN Pseudotyped Lentivirus Generates Therapeutically Relevant and Long-Lasting Alpha-1-Antitrypsin Expression in Mouse Lung. Paul-Smith MC et al.
     
  4. Production of Therapeutically Relevant Levels of FVIII After Transduction of Lungs With F/HN-Pseudotyped Lentivirus. Pytel KM et al.
     

Broken Arrow Conference Gene Discovery to Personalized Medicine Agenda, Toronto. 05-01 to 05-03.

  1. The UK CF Gene Therapy Trial. Gill DR et al.
     

Radcliffe Department of Medicine, Annual Symposium, Oxford. 02-02 .

  1. Lung antibody factory to provide long-term passive immunity to influenza. Tan TK et al.
     

2014

British Thoracic Society Winter Meeting, London. 12-03 to 12-05.

  1. Standardisation of Lung Clearance Index in a Multicentre Clinical Trial. Armstrong DK et al.
     
  2. Reliability of Measurements Using Innocor Beath by Breath Analyser During a Maximal Exercise Test in Cystic Fibrosis Patients. Bayfield KJ et al.
     
  3. Immune Responses to Single and Repeated Administration of pGM169/GL67A, The UK CF Gene Therapy Consortium Clinical Trials. Griesenbach U et al.
     
  4. Development of an optimal F/HN pseudotyped SIV vector for CF gene therapy. Hyde SC et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Washington DC. 05-20 to 05-24.

  1. A phase IIb Double-Blind Placebo-Controlled Trial of Non-Viral Gene Transfer for Cystic Fibrosis. Pringle IA et al.
     
  2. Clinical Development of an Optimal F/HN Pseudotyped SIV Vector for Cystic Fibrosis Lung Gene Therapy. Pringle IA et al.
     

3rd Minicircle & DNA Vector Conference., Bielefeld. 05-08 to 05-09.

  1. Persistent gene expression in the murine lung is dependent on transgene CpG content. Oliveira C et al.
     

The British Society of Gene Therapy Annual Conference, London. 03-25 .

  1. Gene Therapy: Barriers to Translation. Davie N et al.
     
  2. Alpha-1-antitrypsin gene therapy for lung disease. Paul-Smith M et al.
     

2013

The European Society of Gene and Cell Therapy, Madrid. 10-25 to 10-28.

  1. Cholesterol as an enhancer of lentiviral vector production in serum-free transient transfection. Gelinas JF et al.
     
  2. Non-Viral CFTR Gene Delivery To The Lungs Of Cystic Fibrosis Patients. Hyde SC et al.
     

Oxbridge Canadian Conference, Canada House, London. 06-01 .

  1. Gene Therapy for Cystic Fibrosis: Going Viral. Gelinas JF et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Salt Lake City. 05-15 to 05-18.

  1. Lentiviral-Mediated ENaCα Knockdown, as a Treatment for Cystic Fibrosis Lung Disease Harding-Smith RE et al.
     

Radcliffe Department of Medicine, Inaugural Symposium, Oxford. 03-25 .

  1. The use of Lentiviral vectors to treat airway disease. Harding-Smith RE et al.
     
  2. Developing a persistent, inflammation-free gene therapy for Cystic Fibrosis lung disease. Pringle IA et al.
     

2012

British Thoracic Society Winter Meeting, London. 12-05 to 12-07.

  1. Update on The UK CF Gene Therapy Consortium Multidose, Non-Viral, Gene Therapy Trial. Alton EW et al.
     
  2. Repeat Administration of Gl67A/pGM169 Is Feasible, Safe, and Produces Endogenous Levels of CFTR Expression After 12 Doses. Alton EW et al.
     
  3. Assessment of FHN-Pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy. Griesenbach U et al.
     

The European Society of Gene and Cell Therapy, Versailles. 10-26 to 10-29.

  1. Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung. Sumner-Jones SG et al.
     

The North American Cystic Fibrosis Conference, Orlando. 10-11 to 10-13.

  1. Update on the UK CF Gene Therapy Consortium Multidose, Non-viral, Gene Therapy Trial Alton EW et al.
     
  2. The Importance of Appropriate Reference Sources for Spirometry: Lessons Learned from the UK Cystic Fibrosis Gene Therapy Davies G et al.
     
  3. Assessment of F/HN-Pseudotyped Lentivirus in a Clinically Relevant Vector for Lung Gene Therapy Griesenbach U et al.
     

Malaysian Tissue Engineering and Regenerative Medicine Scientific Meeting, Langkawi. 06-03 to 06-04.

  1. Gene Therapy for Cystic Fibrosis Lung Disease. Gill DR et al.
     
  2. Translating Gene Therapy Research Ideas to the Clinical Trials. Hyde SC et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Philidelphia. 05-15 to 05-21.

  1. Large-Scale cGMP Manufacture of a Plasmid Vector for Cystic Fibrosis Gene Therapy Clinical Trials. Cai Y et al.
     
  2. Cell culture models of non-viral transgene expression are not indicative of in vivo lung outcome (2012) Oliveira CA et al.
     

2011

British Thoracic Society Winter Meeting, London. 12-07 to 12-09.

  1. Safety and expression of a single dose of lipidmediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis. Davies G et al.
     

The North American Cystic Fibrosis Conference, Anaheim. 11-03 to 11-05.

  1. Mutliple Doses of Lipid Mediated Gene Therapy Nebulised to the Mouse Lung Show Robust and Sustained CFTR Expression. Hyde SC et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Seattle. 05-18 to 05-21.

  1. The nuclear pore dilating Agent TCHD increases gene transfer into differentiated airway epithelium ex vivo, but has no efect in vivo. Griesenbach U et al.
     
  2. Knockdown of ENaCα, as a treatment for Cystic Fibrosis lung disease Harding-Smith RE et al.
     
  3. Strain-Specific Differences in Pulmonary Gene Transfer Efficiency: Relevance for Toxicology Studies in Mice. Legakis G et al.
     
  4. Self-Reactive T Cells to CFTR in Cystic Fibrosis (CF) and Non-CF Humans: Implications for Gene Therapy. Limberis MP et al.
     

2010

British Thoracic Society Winter Meeting, London. 12-01 to 12-03.

  1. Longitudinal assessment of biomarkers for clinical trials of novel therapeutic agents: the Run-In study. Alton EW et al.
     
  2. Lung clearance index, FEV1 and CT findings in Cystic Fibrosis: data from the UK CF Gene Therapy Consortium Run-in study. Sheridan HS et al.
     

The North American Cystic Fibrosis Conference, Baltimore. 10-21 to 10-23.

  1. Development, Production and Evaluation of clinical grade CFTR Expression Plasmid for CF Lung Gene Therapy Gill DR et al.
     
  2. Concentrated PEI Gene Transfer formulations retain biological efficacy following long-term storage at 4C. Hyde SC et al.
     

The American Society of Gene and Cell Therapy Annual Conference, Washington DC. 05-19 to 05-23.

  1. Genomic DNA Reduction for Therapeutic DNA Manufacture. Cai Y et al.
     
  2. Concentrated PEI Formulations Retain Biological Efficacy Following Long-Term Storage at 4C. Davies LA et al.
     
  3. SIV Vector Pseudotyped with SeV-F/HN Envelope Proteins Produces Long Lasting Expression in the Murine Lung, Is Readministrable and Transfects Human Airway Models. Griesenbach U et al.
     
  4. A clinical study to evaluate the safety and efficacy of pGM169/GL67A administered to the nose and lungs of individuals with cystic fibrosis. Hyde SC et al.
     
  5. Repeat Aerosol Delivery of Concentrated PEI/pDNA to the Sheep Lung. McLachlan G et al.
     
  6. Duration of Expression from CpG-Free Plasmids Following Hydrodynamic Delivery to the Mouse. Pringle IA et al.
     

2009

The European Society of Gene and Cell Therapy Conference, Hannover. 11-20 to 11-25.

  1. Quantifying non-viral gene transfer by real-time PCR: a cautionary tale. Coles R et al.
     

The North American Cystic Fibrosis Conference, Minneapolis. 10-14 to 10-19.

  1. 3-Step TaqMan RT-PCR: Ultimate mRNA Detection Sensitivity For CF Gene Therapy Clinical Trials. McCormick D et al.
     
  2. Optimisation of molecular assays for clinical trial of GL67A/pGM169 delivery to nose and lung of CF patients. Sumner-Jones SG et al.
     

1000 years of pharmaceutical aerosols What remains to be done?, Reykjavik. 10-01 to 10-02.

  1. Aerosol Delivery of Gene Therapeutics to the Lung. Davies LA et al.
     

The American Society of Gene Therapy Annual Conference, San Diego. 05-26 to 05-30.

  1. The Effect of pDNA Quality on Gene Transfer Outcome In Vivo. Bazzani RP et al.
     
  2. A Novel Mixing Device for the Reproducible Manufacture of Non-Viral Gene Therapy Formulations. Davies LA et al.
     
  3. Secreted Gaussia Luciferase Is a More Sensitive Reporter Than Firefly Luciferase for Non- Viral Gene Transfer to Airway Epithelium Ex Vivo and In Vivo. Griesenbach U et al.
     
  4. Salt Concentration and Liposomal DNA Therapeutic Formulations. Nicholls P et al.
     
  5. Repeated Exposure to pDNA/PEI Aerosols Results in Minimal Detectable Toxicity in the Mouse Lungs . Nunez-Alonso GA et al.
     
  6. Calculating the percentage of cells transfected following non-viral delivery to the respiratory epithelium. Pringle IA et al.
     
  7. Optimising Harvest of Bronchial Brush Biopsy Samples To Maximise Cell and RNA Yield in Gene Therapy Studies. Vrettou C et al.
     

The British Society of Gene Therapy Annual Conference, London. 04-21 to 04-23.

  1. Non-viral gene expression in the lung using the mini-CFTR promoter. Connolly MM et al.
     
  2. Inflammation-Free shRNA Expression Vectors for Cystic Fibrosis Gene Therapy. Lawton AE et al.
     

2008

European Society of Gene and Cell Therapy Conference, Bruges. 11-13 to 11-16.

  1. CpG Free Plasmids For Enhanced Duration & Reduced Toxicity Of Non-Viral Airway Gene Transfer. Hyde SC et al.
     

The North American Cystic Fibrosis Conference, Orlando. 10-23 to 10-25.

  1. Aerosol Characteristics of DNA/lipid Formulations for Gene Therapy Clinical Studies. Gill DR et al.
     
  2. Inflammation-free Human and Murine Promoters for Non-viral CFTR Lung Gene Therapy. Hyde SC et al.
     

The American Society of Gene Therapy Annual Conference, Boston. 05-28 to 06-01.

  1. Optimisation of Aerosol Delivery of Lipid/DNA Complexes for Clinical Studies. Davies LA et al.
     
  2. Challenges in the Process Development of a Novel Zero CpG CFTR Plasmid for Human Clinical Use. Hebel HL et al.
     
  3. Non-Viral Vector Development For Reduced Inflammation and Sustained Pulmonary Gene Expression. Hyde SC et al.
     
  4. Towards Gene Therapy for Cystic Fibrosis: Bio-Distribution of GL67A/pGM169 DNA and mRNA Following Aerosol Delivery to the Mouse Lung. Pringle IA et al.
     
  5. Identification of Novel Naturally CpG-Free Human and Murine Promoters for Non-viral Gene Therapy. Pringle IA et al.
     
  6. Near-Single Copy mRNA Quantification from a TaqMan RT-PCR Assay for an Aerosol Gene Therapy Clinical Trial. Sumner-Jones SG et al.
     

The British Society of Gene Therapy Annual Conference, Edinburgh. 04-07 to 04-09.

  1. Adenovirus-mediated in utero expression of CFTR does not improve survival of CFTR knockout mice. Davies L et al.
     
  2. Development of highly sensitive TaqMan RT-PCR assays for quantifying vector mRNA in human samples. Sumner-Jones SG et al.
     

2007

The North American Cystic Fibrosis Conference, Anaheim. 10-03 to 10-06.

  1. Influence of CpG-dinuceotide motifs on the duration of duration of gene expression from plasmid vectors after in vivo lung delivery. Gill DR et al.
     
  2. EnaC Knockdown in the Mouse Lung using RNAI. Hyde SC et al.
     

The American Society of Gene Therapy Annual Conference, Seattle. 05-30 to 06-03.

  1. CpG-Dependent Inflammatory Response after Delivery of Lipid/pDNA Complexes to Murine Lungs. Bazzani RP et al.
     
  2. Aerosol Delivery of Concentrated pDNA/PEI Formulations to the Sheep Lung. Davies LA et al.
     
  3. Influence of the Human and Murine CMV Enhancer on the Duration of Expression from CpG-Free pDNA Vectors in the Mouse Lung. Green A-M et al.
     
  4. CpGs Influence the Duration of Gene Expression from Plasmid Vectors after In Vivo Lung Delivery. Lawton AE et al.
     
  5. Persistent Gene Expression in the Ovine Lung from a Human Elongation Factor 1 Alpha Promoter Plasmid Following Non-Viral Gene Delivery. McLachlan G et al.
     
  6. Long-Term Stability of Aqueous pDNA/PEI Complexes. Nunez-Alonso GA et al.
     
  7. Generation of a CpG-Free Clinical Trial Plasmid for Cystic Fibrosis Lung Gene Therapy. Pringle IA et al.
     

1st International Workshop on Minicircle DNA, Bielefeld. 02-21 to 02-22.

  1. CpG-Free Plasmids for Cystic Fibrosis Gene Therapy. Gill DR et al.
     

2006

North American Cystic Fibrosis Conference, Denver. 11-02 to 11-05.

  1. Complete but not Partial Reduction of Plasmid CpG Content Increases Transgene Expression and Eliminates the Inflammatory Response Associated with Delivery of Non-Viral Vectors to the Lung. Hyde SC et al.
     

The American Society of Gene Therapy Annual Conference, Baltimore. 05-31 to 06-04.

  1. Aerosol Delivery of Concentrated pDNA/PEI Formulations to the Murine Lung. Davies LA et al.
     
  2. Development of Zero-CpG Plasmids with Reduced Inflammatory Responses Following Delivery of Lipid/pDNA Complexes to the Mouse Lung. Pringle IA et al.
     

British Society of Gene Therapy Conference, London. 03-28 to 03-30.

  1. EGFP expression in the mouse lung following administration of gene transfer vectors expressing EGFP from the UbC promoter. Davies LA et al.
     
  2. CpG depletion results in increased duration of gene expression from plasmid DNA vectors in vivo. Lawton AE et al.
     
  3. Complete but not partial reduction of plasmid CpG content reduces the inflammatory response associated with delivery of GL67/pDNA complexes to the mouse lung. Pringle IA et al.
     
  4. Reduced reporter activity upon repeated administration of adeno-associated virus 5 in murine airways. Sumner-Jones SG et al.
     
  5. Novel CpG depleted and codon optimised CFTR cDNAs maintain the structure and fuction of CFTR protein. Varathalingam A et al.
     

2005

The European Society of Gene and Cell Therapy Conference, Prague. 10-29 to 11-01.

  1. Development of zero-CpG plasmids for noviral lung gene therapy. Pringle IA et al.
     
  2. Repeat administration of adenoassociated virus 5 in murine airways. Sumner-Jones SG et al.
     

The North American Cystic Fibrosis Conference, Baltimore. 10-20 to 10-23.

  1. Optimising Gene Transfer Products for Evaluation in the Mouse Nasal Epithelium. Hyde SC et al.
     
  2. CpG Depletion Results in Increased Duration of Gene Expression from Plasmid DNA Vectors In vivo. Lawton AE et al.
     
  3. Avoiding the Nuclear Barrier: The Development of mRNA as a Gene Transfer Agent. Painter H et al.
     
  4. Novel CPG-Depleted and Codon-Optimised CFTR CDNAs Maintain the Structure and Function of CFTR Protein. Varathalingam A et al.
     

The American Society of Gene Therapy Annual Conference, St Louis. 06-01 to 06-05.

  1. Repeat Administration of Polyethylenimine (PEI) Aerosols of Plasmid DNA to the Murine Lung is Associated with a Loss of Gene Transfer Efficiency. Davies LA et al.
     
  2. Development of Quantitative TaqMan RT-PCR for the Evaluation of Non-Viral Mediated Gene Transfer to the airways. Pringle IA et al.
     
  3. Using Real-Time (TaqMan) PCR to Genotype Offspring of Transgenic CF-null Mice- A Core Facility of the UK Cystic Fibrosis Gene Therapy Consortium. Smith RL et al.
     

2004

The European Cystic Fibrosis Conference, Birmingham. 06-13 to 06-17.

  1. Transgene Expression in the Mouse Lung following Administration of Gene Transfer Vectors Expressing EGFP. Davies LA et al.
     
  2. Evaluating Gene Transfer Products for Gene Expression in Mouse Nasal Epithelium. Jones BL et al.
     
  3. Direct Electroporation of the Murine Lung greatly Enhances Reporter Gene Expression following Intranasal Delivery of Plasmid DNA. Pringle IA et al.
     
  4. Using real-time (Taqman) RT-PCR to measure gene expression- a core facility of the UK . Smith RL et al.
     
  5. Repeat Administration of Adeno-associated Virus in Murine Airways. Sumner-Jones SG et al.
     

The American Society of Gene Therapy Annual Conference, Minneapolis. 06-02 to 06-06.

  1. Use of Ciliated Cell Specific Promoter FoxJ1 in Gene Transfer Vectors for the Airway Epithelium. Lawton AE et al.
     
  2. Topical Delivery of mRNA to the Murine Lung and Nasal Epithelium. Painter H et al.
     
  3. Duration of Reporter Gene Expression from Naked pDNA in the Mouse Lung following Direct Electroporation and Development of Wire Electrodes for Sheep Lung Electroporation Studies. Pringle IA et al.
     
  4. Delivery of NF-κβ Decoy Related Oligodeoxynucleotides Reduces Pro-Inflammatory Cytokine Responses Associated with Plasmid DNA/Lipid Mediated Gene Transfer to Murine Lungs. Varathalingam A et al.
     

2003


2002


2001


 

A pellet of E.coli containing a plasmid expressing a pink fluorescent protein.

 

E.coli from a large scale industrial production of our clinical trial plasmid pGM169.

 

Human airway liquid interface cultures transduced with a lentivirus expressing Luciferase.

 

A frozen vial of GL67A (left) and a frozen vial of pGM169 plasmid DNA (right)

 

Proposed 3D model of the CFTR protein.

 

A CFTR Western blot, to confirm protein production in cell culture.

 

Light microscope image of a human airway liquid interface cultures. Dark patches are mucous.

 

Mouse lung large airway (cell nuclei blue) transduced with an adenoviral vector (green).

 

Sheep lung parenchyma (cell nuclei blue) transduced with an adenoviral vector (green).

 

Large scale lentivirus production in suspension culture.

 

Schematic diagram of the large human airways.

 

A cake that only some of us got to enjoy!

 

Purifying mRNA from tissue samples.

 

Pellets of DNA following precipitation.

 

DNA fragments being cut from an agarose gel exposed to UV.